Central illustration.

Cangrelor — indications, main pharmacological features, and mechanism of action. Cangrelor may be considered in P2Y12-inhibitor-naïve patients undergoing percutaneous coronary intervention (PCI) for both acute coronary syndrome (ACS) and chronic coronary syndrome (CCS). It is an intravenous adenosine triphosphate analog that reversibly binds to platelet P2Y12 receptors and is characterized by rapid and potent platelet inhibition after an intravenous bolus followed by a continuous infusion, as well as quick offset of antiplatelet effect after discontinuation of infusion thanks to a rapid metabolism.